Organon & Co. Q3 2025 Earnings Recap

OGN Q3 2025 November 11, 2025

Organon reported third-quarter 2025 revenue of $1.6 billion with an adjusted EBITDA of $518 million, despite ongoing challenges related to improper sales practices for its Nexplanon product.

Earnings Per Share Beat

$1.01 vs $0.93 est.

+8.6% surprise

Revenue Beat

1602000000 vs 1521952710 est.

+5.3% surprise

Market Reaction

1-Day -2.46%

5-Day -2.33%

30-Day -7.39%

Key Takeaways

Third-quarter revenue of $1.6 billion represents steady demand, reflecting the resilience of the product portfolio.
Adjusted EBITDA margin improved to 32.3%, indicating effective cost management despite operational hurdles.
An internal investigation into sales practices concluded with limited revenue impact and no need for financial restatements.
New leadership has been appointed to oversee remediation efforts, ensuring compliance and operational excellence moving forward.
The company remains committed to its strategic priorities of deleveraging and revenue growth amid ongoing changes in management.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit OGN on AllInvestView.